Imagine your body has a silent alarm system that goes off long before you actually get sick. This project looks at the connection between what we eat, our gut bacteria, and inflammation to spot the exact moment a healthy person starts sliding toward a disease. By tracking these signals, they can suggest specific diet changes or probiotics to stop the damage before it becomes permanent.
Chronic diseases like type 2 diabetes and heart disease are often detected only after irreversible organ damage has occurred. There is a lack of personalized, real-time tools to detect the subclinical inflammation that precedes these conditions.
The project is building the IMMEDI-APP for lifestyle monitoring and a comprehensive database of omics profiles linked to health-to-disease transitions.
If you are a health app developer dealing with low user retention and generic advice — this project developed the IMMEDI-APP that provides personalized lifestyle and dietary recommendations based on a person's specific inflammation risk score.
If you are a probiotic manufacturer dealing with a lack of clinical evidence for specific strains — this project conducted a proof-of-concept study on Akkermansia muciniphila to evaluate its anti-inflammatory effects on somatic and mental health.
If you are a clinic dealing with late-stage diagnosis of kidney or heart disease — this project developed a list of actionable risk and resilience factors that can be used to create new prevention guidelines.
Based on available project data, no pricing or cost information for the IMMEDI-APP or the biomarkers is provided.
The project includes 5 SMEs and 13 partners across 7 countries, suggesting a collaborative structure capable of scaling, though industrial scale metrics are not specified.
Based on available project data, specific IP or licensing terms are not mentioned; however, the project generates a database of omics profiles and actionable risk factors.
The project uses a data management plan to combine datasets from well-characterized cohorts and multi-omics with clinical data and biospecimens.
The project period runs from 2023-01-01 to 2026-12-31, indicating that final results and tools will be ready by the end of 2026.
The consortium is well-balanced for commercialization, featuring a 38% industry ratio with 5 SMEs and 6 universities. With 13 partners across 7 countries, the project combines high-level academic research from Charité Berlin with agile SME implementation, specifically targeting the transition from clinical omics data to a consumer-facing digital application.
Contact Charité - Universitätsmedizin Berlin regarding the IMMEDI-APP and omics database.
Request a detailed analysis of the Akkermansia muciniphila proof-of-concept results.
